The forthcoming committee meeting to discuss volanesorsen for treating familial chylomicronaemia syndrome has been rearranged. This is to allow the company (Akcea Therapeutics) additional time to prepare their submission for consideration by the HST committee.
Volanesorsen for treating familial chylomicronaemia syndrome will be now considered by committee on Thursday 28 November 2019.